Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.72 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.49 |
| ▸ | ACP3 | P15309 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16412856 | 1.00 | PNMT (0.72) | PNMTCES2GRIN2BACP3IDO1 | |
| SCHEMBL29256522 | 1.00 | PNMT (0.72) | PNMTCES2GRIN2BACP3IDO1 | |
| SCHEMBL30988809 | 0.86 | PNMT (0.54) | PNMTCES2GRIN2BCHRM2CHRM4 | |
| SCHEMBL29256530 | 0.86 | PNMT (0.54) | PNMTCES2GRIN2BCHRM2CHRM4 | |
| SCHEMBL29256529 | 0.86 | PNMT (0.54) | PNMTCES2GRIN2BCHRM2CHRM4 | |
| SCHEMBL3198162 | 0.86 | PNMT (0.68) | PNMTCES2GRIN2BACP3IDO1 | |
| SCHEMBL7109755 | 0.85 | PNMT (0.72) | PNMTCES2GRIN2BACP3IDO1 | |
| SCHEMBL7152130 | 0.84 | PNMT (1.00) | PNMTCES2GRIN2BACP3IDO1 | |
| SCHEMBL30753488 | 0.84 | PNMT (1.00) | PNMTCES2GRIN2BACP3IDO1 | |
| SCHEMBL166671 | 0.84 | PNMT (1.00) | PNMTCES2GRIN2BACP3IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118340754-B | Compound for treating heart failure and related diseases and application thereof | 源道医药(苏州)有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-118340754-A | Compound for treating heart failure and related diseases and application thereof | 源道医药(苏州)有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| US-4588749-A | ANTIOBESITY AND HYPOGLYCEMIC AGENTS | BEECHAM GROUP P.L.C. (GB) | 1986-05-13 | — | — | US | disclosed |
| EP-0040000-B1 | ARYLETHANOLAMINE DERIVATIVES, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1983-10-12 | — | — | EP | disclosed |
| EP-0040000-A1 | Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | PNMT 175/4885CES2 3378/4885GRIN2B 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.